FDA Grants Orphan Drug Designation to GC Biopharma’s Drug Candidate for Thrombotic Thrombocytopenic Purpura

GC Biopharma Corp. announced that GC1126A, its drug candidate for Thrombotic Thrombocytopenic Purpura, received an Orphan Drug Designation on September 27 from the U.S. Food and Drug Administration.